EMERYVILLE, Calif., March 1, 2017 /PRNewswire/ -- Gritstone Oncology, Inc. announced that Andrew Allen, M.D., Ph.D., the company's president and chief executive officer, will present at Cowen and Company's 37th Annual Health Care Conference in Boston, Mass., on Wednesday, March 8 at 9:30 a.m. Eastern Standard Time.
The Cowen and Company Health Care Conference brings together industry leaders and top investors through company presentations, interviews, and panel discussions.
About Gritstone Oncology: Gritstone Oncology is a privately-held cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company's initial goal is to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop novel treatments for lung cancer. Gritstone Oncology is headquartered in the San Francisco Bay Area with certain key functions located in Cambridge, Mass. Gritstone Oncology launched in October 2015 with a Series A financing of $102 million. More information can be found at www.gritstone.com.
Contact:Michele ParisiFor Gritstone [email protected]
Advertisement
The Cowen and Company Health Care Conference brings together industry leaders and top investors through company presentations, interviews, and panel discussions.
Advertisement
About Gritstone Oncology: Gritstone Oncology is a privately-held cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company's initial goal is to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop novel treatments for lung cancer. Gritstone Oncology is headquartered in the San Francisco Bay Area with certain key functions located in Cambridge, Mass. Gritstone Oncology launched in October 2015 with a Series A financing of $102 million. More information can be found at www.gritstone.com.
Contact:Michele ParisiFor Gritstone [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gritstone-oncology-to-present-at-cowen-and-companys-37th-annual-health-care-conference-300414018.html
SOURCE Gritstone Oncology, Inc.
